Verbascoside reverses GABAergic deficits in the prefrontal cortex to alleviate chronic Stress-Induced depression.

IF 3.3 3区 医学 Q2 NEUROSCIENCES
Jin Pan, Liuxuan Huang, Peng Sun, Haoquan Tian, Wenguang Yang, Xinyu Fang, Feng Li, Ke Ma
{"title":"Verbascoside reverses GABAergic deficits in the prefrontal cortex to alleviate chronic Stress-Induced depression.","authors":"Jin Pan, Liuxuan Huang, Peng Sun, Haoquan Tian, Wenguang Yang, Xinyu Fang, Feng Li, Ke Ma","doi":"10.1007/s00213-025-06894-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The dysregulation of prefrontal synaptic transmission accompanied by γ-aminobutyric acid (GABA) deficit, is crucial in depression. Previously, we have demonstrated that Baihe Dihuang decoction with verbascoside (VB) as one of the main active ingredients attenuates prefrontal interneurons deficits through synthesis and release of GABA negatively regulated by miR-144-3p, but the potential mechanism through which VB reverses the dysfunction of stress-induced aberrant prefrontal GABAergic neurons through miRNAs/Gad-67/VGAT signaling remains elusive.</p><p><strong>Methods: </strong>The antidepressant effects and neuroprotective function of VB were observed by a chronic stress-induced depression and corticosterone (CORT)-stimulated nerve cell injury model, respectively. Specific changes in prefrontal GABAergic miR-144-3p expression were used to assess the action of VB acting on GABA release.</p><p><strong>Results: </strong>High-expression prefrontal miR-144-3p was associated with depression-like behaviors caused by long time stress, reflected by altered GABA tone. Supplementation with VB attenuated chronic stress-induced prefrontal cortex neuron injury and prefrontal GABAergic deficit by downregulating miR-144-3p expression, as well as obviously improved the relative abundance of beneficial GABA-producing bacteria. However, antidepressant-like effects by VB were antagonized by overexpressed miR-144-3p in frontal cortex GABAergic neurons. Similarly, VB administration caused reduced expression of miR-144-3p against impaired GABA production. In the CORT-induced nerve cell injury model, The pharmacological effect of VB promoting GABA release ability and exerting neuroprotection is strongly reversed by overexpression of miR-144-3p.</p><p><strong>Conclusion: </strong>This study elucidated that miR-144-3p down-regulated GABAergic neurons activation in the medial prefrontal cortex was sufficient and necessary for VB antidepressant responses.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00213-025-06894-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The dysregulation of prefrontal synaptic transmission accompanied by γ-aminobutyric acid (GABA) deficit, is crucial in depression. Previously, we have demonstrated that Baihe Dihuang decoction with verbascoside (VB) as one of the main active ingredients attenuates prefrontal interneurons deficits through synthesis and release of GABA negatively regulated by miR-144-3p, but the potential mechanism through which VB reverses the dysfunction of stress-induced aberrant prefrontal GABAergic neurons through miRNAs/Gad-67/VGAT signaling remains elusive.

Methods: The antidepressant effects and neuroprotective function of VB were observed by a chronic stress-induced depression and corticosterone (CORT)-stimulated nerve cell injury model, respectively. Specific changes in prefrontal GABAergic miR-144-3p expression were used to assess the action of VB acting on GABA release.

Results: High-expression prefrontal miR-144-3p was associated with depression-like behaviors caused by long time stress, reflected by altered GABA tone. Supplementation with VB attenuated chronic stress-induced prefrontal cortex neuron injury and prefrontal GABAergic deficit by downregulating miR-144-3p expression, as well as obviously improved the relative abundance of beneficial GABA-producing bacteria. However, antidepressant-like effects by VB were antagonized by overexpressed miR-144-3p in frontal cortex GABAergic neurons. Similarly, VB administration caused reduced expression of miR-144-3p against impaired GABA production. In the CORT-induced nerve cell injury model, The pharmacological effect of VB promoting GABA release ability and exerting neuroprotection is strongly reversed by overexpression of miR-144-3p.

Conclusion: This study elucidated that miR-144-3p down-regulated GABAergic neurons activation in the medial prefrontal cortex was sufficient and necessary for VB antidepressant responses.

毛蕊花苷逆转前额皮质gaba能缺陷以减轻慢性应激性抑郁症。
背景:伴随γ-氨基丁酸(GABA)缺失的前额叶突触传递失调是抑郁症的重要机制。此前,我们已经证实以毛bascoside (VB)为主要活性成分之一的百合地黄汤通过miR-144-3p负调控GABA的合成和释放来减轻前额叶中间神经元的功能缺陷,但VB通过miRNAs/Gad-67/VGAT信号逆转应激诱导的异常前额叶GABA神经元功能障碍的潜在机制尚不明确。方法:采用慢性应激性抑郁模型和皮质酮刺激神经细胞损伤模型,分别观察VB的抗抑郁作用和神经保护作用。我们用前额叶GABA能miR-144-3p表达的特异性变化来评估VB对GABA释放的作用。结果:高表达的前额叶miR-144-3p与长时间应激引起的抑郁样行为相关,表现为GABA音调的改变。补充VB可通过下调miR-144-3p表达减轻慢性应激性前额皮质神经元损伤和前额叶gaba能缺陷,并明显提高有益gaba产生菌的相对丰度。然而,VB的抗抑郁样作用被额叶皮质gaba能神经元中过表达的miR-144-3p所拮抗。同样,给药VB导致miR-144-3p的表达降低,从而抑制GABA的产生。在cort诱导的神经细胞损伤模型中,VB促进GABA释放能力和发挥神经保护作用的药理作用被miR-144-3p过表达强烈逆转。结论:本研究阐明了miR-144-3p下调内侧前额叶皮层gaba能神经元激活对VB抗抑郁反应是充分和必要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Psychopharmacology
Psychopharmacology 医学-精神病学
CiteScore
7.10
自引率
5.90%
发文量
257
审稿时长
2-4 weeks
期刊介绍: Official Journal of the European Behavioural Pharmacology Society (EBPS) Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields: Human Psychopharmacology: Experimental This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered. Human Psychopharmacology: Clinical and Translational This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects. Preclinical psychopharmacology: Behavioral and Neural This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels. Preclinical Psychopharmacology: Translational This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways. Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信